NCT03742258 2025-06-18
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
Phase 1 Completed
Clinical Trials
13 trialsNCT04079738 2023-09-13
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT03756818 2023-02-28
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02000934 2023-02-08
A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies
Calithera Biosciences, Inc
Phase 1 Completed
NCT02323113 2023-02-08
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Calithera Biosciences, Inc
Phase 1/2 Terminated
NCT02834247 2023-02-08
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
Phase 1 Terminated
NCT03123393 2023-02-08
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Calithera Biosciences, Inc
Phase 2 Terminated
NCT03238651 2023-02-08
A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
Phase 1 Terminated
NCT03338881 2023-02-08
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT03357627 2023-02-08
A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma
Calithera Biosciences, Inc
Phase 1 Completed
NCT03359733 2023-02-08
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT03772288 2023-02-08
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT02954406 2022-02-18
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Takeda
Phase 1 Terminated